When bleeding is the consequence of a specific defect of hemostasis, the goal of treatment
is to correct the defect. A typical example is the replacement of factor VIII by transfusion in …

Several biomaterials can be obtained from human blood. Some are used for clinical
indications requiring a high content in fibrinogen, while others are used because they …

Growth factors released from activated platelets initiate and modulate wound healing in both
soft and hard tissues. A recent strategy to promote the wound-healing cascade is to prepare …

The need to effectively manage hemostasis and tissue sealing during surgery has had a
strong influence on the development of modern surgical techniques. A group of agents …

Background: Total knee arthroplasty is associated with major postoperative blood loss of
approximately 800 to 1200 milliliters, and blood transfusion is frequently required. With the …

Fibrin sealant (fibrin adhesive; fibrin glue; Beriplast® P 1) is a haemostatic and wound
support product consisting of the blood coagulation factors fibrinogen, factor XIII and …

Fibrin sealants can be a valuable adjunct to surgical procedures. A variety of commercial
products have been developed. Specific uses include hemostasis, tissue sealing, and even …

Background: Recombinant activated factor VII (rFVIIa) has been approved by the US Food
and Drug Administration (FDA) for almost a decade for hemophilic patients with inhibitors. Its …

Fresh platelet concentrates are used in many centers to treat recalcitrant wounds. To extend
the therapeutic shelf‐life of platelets, we analyzed the wound‐healing effects of fresh‐frozen …

If continuous prophylaxis is not feasible due to expense or lack of venous access, we must
aggressively treat major haemarthroses (including arthrocentesis) to prevent progression to …